100 citations
,
April 2010 in “Expert Opinion on Pharmacotherapy”
This article reviews existing treatments for male-pattern hair loss, noting that while they can slow progression, they generally achieve only partial hair regrowth.
87 citations
,
March 2011 in “Australasian Journal of Dermatology”
This review explores the current understanding of genetic and hormonal influences on maleandrogeneticalopecia and female pattern hair loss, providing guidance for clinicians but reports no new results.
54 citations
,
July 2002 in “Clinical and Experimental Dermatology”
This article provides a critical overview of recent discoveries in the genetics and molecular processes involved in androgeneticalopecia, focusing on its polygenic basis and DHT dependency, but reports no new clinical results.
52 citations
,
May 2019 in “Journal of The American Academy of Dermatology”
This study evaluated the effectiveness and safety of low-dose oral minoxidil (2.5-5 mg daily) in men with maleandrogeneticalopecia, aiming to contribute data to an area with limited previous reports. Results are not provided in the abstract.
41 citations
,
January 2009 in “International Journal of Trichology”
This study found that 58% of men aged 30-50 had androgenicalopecia, with disease severity increasing with age and many being candidates for medical treatment or hair transplantation.
A young man faces severe hair loss in his early 20s, using treatments like dutasteride and minoxidil with little success, impacting his self-esteem and relationships. He considers hair systems and therapy as potential solutions.
The conversation discusses a botanically derived treatment for androgeneticalopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.
Oral dutasteride 0.5 mg combined with oral minoxidil 2.5 mg is highly effective for maleandrogeneticalopecia, showing over 60% improvement and 98% stabilization at 6 months, with low adverse event rates. Patients with severe baseline conditions respond better and faster to this treatment.
A 24-year-old male with aggressive androgeneticalopecia is using 1mg finasteride daily and considering a treatment stack including 0.5mg dutasteride, 2.5mg oral minoxidil, ketoconazole shampoo, Alpecin caffeine shampoo, and RU58841. He seeks advice on the safety and effectiveness of these treatments and whether any adjustments are needed.
A 27-year-old male physician improved hair density using minoxidil 5% foam and finasteride 1mg every other day, with initial sexual side effects that subsided. He recommends trying finasteride for a year but warns against dutasteride due to potential liver effects.
Frontline, gold standard treatment for combatting androgenicalopecia
Is Finasteride unbeatable or are there equally powerful alternatives?Trials report finasteride as the single medication with the strongest measured effect in male androgenetic alopecia, while dutasteride, minoxidil, topical finasteride, PRP, LLLT and microneedling all have supporting studies and are often reported to work better in combination. Finasteride, dutasteride and oral minoxidil are prescription-only, and several of these uses are off-label.